In patients with SCD or MCI with abnormal pTau217 levels (who would be referred to a tau-PET scan in our proposed workflow) (Fig. 4A), the model containing tau-PET SUVr values and demographics had the highest added value for predicting cognitive decline (R2 = 29.8%; wAIC = 0.67) and performed significantly better when compared to the demographics-only model (R2 = 5.1%; wAIC = 0) and the plasma pTau217 plus demographics model (R2 = 13.8%; wAIC = 0). This evidence concerns the gene MAPT and Mental deterioration.